| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Health Effects of Overweight and Obesity in 195 Countries over 25 Years.
|
N Engl J Med
|
2017
|
3.90
|
|
2
|
Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study.
|
Am J Psychiatry
|
2013
|
1.75
|
|
3
|
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015.
|
Lancet HIV
|
2016
|
1.51
|
|
4
|
Specificity of cognitive deficits in bipolar disorder versus schizophrenia. A systematic review.
|
Psychother Psychosom
|
2006
|
1.36
|
|
5
|
Neurocognitive endophenotypes (endophenocognitypes) from studies of relatives of bipolar disorder subjects: a systematic review.
|
Neurosci Biobehav Rev
|
2008
|
1.23
|
|
6
|
Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577,013 participants of 50 observational studies.
|
Psychother Psychosom
|
2014
|
1.15
|
|
7
|
Persistent cognitive dysfunctions in bipolar I disorder and schizophrenic patients: a 3-year follow-up study.
|
Psychother Psychosom
|
2005
|
1.02
|
|
8
|
Therapeutic use of omega-3 fatty acids in bipolar disorder.
|
Expert Rev Neurother
|
2011
|
0.99
|
|
9
|
Bipolar I patients with and without a history of psychotic symptoms: do they differ in their cognitive functioning?
|
J Psychiatr Res
|
2006
|
0.99
|
|
10
|
Poor long-term prognosis in mixed bipolar patients: 10-year outcomes in the Vitoria prospective naturalistic study in Spain.
|
J Clin Psychiatry
|
2010
|
0.93
|
|
11
|
Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients.
|
Compr Psychiatry
|
2011
|
0.93
|
|
12
|
Long-term outcome of cognitive impairment in bipolar disorder.
|
J Clin Psychiatry
|
2012
|
0.92
|
|
13
|
Comparative study of neurocognitive function in euthymic bipolar patients and stabilized schizophrenic patients.
|
Psychiatry Res
|
2009
|
0.90
|
|
14
|
Neurocognition in bipolar disorders--a closer look at comorbidities and medications.
|
Eur J Pharmacol
|
2009
|
0.89
|
|
15
|
Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S): psychometric properties of a brief scale for cognitive evaluation in schizophrenia.
|
Schizophr Res
|
2007
|
0.84
|
|
16
|
The increasing burden of mental and neurological disorders.
|
Eur Neuropsychopharmacol
|
2013
|
0.83
|
|
17
|
Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
|
Psychiatry Res
|
2012
|
0.82
|
|
18
|
Alzheimer's disease and cancer: current epidemiological evidence for a mutual protection.
|
Neuroepidemiology
|
2014
|
0.82
|
|
19
|
Utility of the World Health Organization Disability Assessment Schedule II in schizophrenia.
|
Schizophr Res
|
2012
|
0.80
|
|
20
|
Psychometric behaviour of the strengths and difficulties questionnaire (SDQ) in the Spanish national health survey 2006.
|
BMC Psychiatry
|
2013
|
0.80
|
|
21
|
Human adult periodontal ligament-derived cells integrate and differentiate after implantation into the adult mammalian brain.
|
Cell Transplant
|
2012
|
0.80
|
|
22
|
Brief cognitive assessment instruments in schizophrenia and bipolar patients, and healthy control subjects: a comparison study between the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) and the Screen for Cognitive Impairment in Psychiatry (SCIP).
|
Schizophr Res
|
2011
|
0.80
|
|
23
|
Neurocognitive diagnosis and cut-off scores of the Screen for Cognitive Impairment in Psychiatry (SCIP-S).
|
Schizophr Res
|
2009
|
0.80
|
|
24
|
Postnatal alterations of the inhibitory synaptic responses recorded from cortical pyramidal neurons in the Lis1/sLis1 mutant mouse.
|
Mol Cell Neurosci
|
2007
|
0.79
|
|
25
|
Clinical usefulness of the screen for cognitive impairment in psychiatry (SCIP-S) scale in patients with type I bipolar disorder.
|
Health Qual Life Outcomes
|
2009
|
0.79
|
|
26
|
One year longitudinal study of the straight gyrus morphometry in first-episode schizophrenia-spectrum patients.
|
Psychiatry Res
|
2012
|
0.79
|
|
27
|
Sex-specific variation of MRI-based cortical morphometry in adult healthy volunteers: the effect on cognitive functioning.
|
Prog Neuropsychopharmacol Biol Psychiatry
|
2011
|
0.78
|
|
28
|
How does family intervention improve the outcome of people with schizophrenia?
|
Soc Psychiatry Psychiatr Epidemiol
|
2014
|
0.78
|
|
29
|
The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia.
|
BMC Psychiatry
|
2010
|
0.77
|
|
30
|
Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
|
Schizophr Res
|
2012
|
0.77
|
|
31
|
Neurocognitive training in patients with bipolar disorders: current status and perspectives.
|
Psychother Psychosom
|
2012
|
0.76
|
|
32
|
Temporal pole morphology in first-episode schizophrenia patients: clinical correlations.
|
Psychiatry Res
|
2010
|
0.76
|
|
33
|
Longitudinal course of cognition in schizophrenia.
|
Br J Psychiatry
|
2009
|
0.76
|
|
34
|
Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.
|
Psychopharmacology (Berl)
|
2013
|
0.76
|
|
35
|
The importance of negative comorbidity.
|
J Clin Psychiatry
|
2009
|
0.75
|
|
36
|
The screen for cognitive impairment in psychiatry: diagnostic-specific standardization in psychiatric ill patients.
|
BMC Psychiatry
|
2013
|
0.75
|
|
37
|
Alzheimer's disease and cancer: the need of putting research into context with previous published systematic reviews.
|
J Cancer Res Clin Oncol
|
2014
|
0.75
|
|
38
|
Straight gyrus morphology in first-episode schizophrenia-spectrum patients.
|
Prog Neuropsychopharmacol Biol Psychiatry
|
2010
|
0.75
|